VELPACLEAR TABLET 28'S

VELPACLEAR TABLET 28'S has shown efficacy in treating hepatitis C in individuals with advanced liver disease or compensated cirrhosis. However, the response rate may vary, and close monitoring of liver function is important during and after treatment.

Yes, regular blood tests are typically conducted during VELPACLEAR TABLET 28'S treatment to monitor liver function, viral load, and treatment response. These tests help assess the effectiveness of the medication and ensure patient safety.

VELPACLEAR TABLET 28'S can be used in patients with mild to moderate kidney impairment without dose adjustment. However, patients with severe renal impairment or end-stage renal disease may require dose adjustments or alternative treatment options. It is important to discuss your kidney function with your healthcare provider to determine the most appropriate treatment plan.

VELPACLEAR TABLET 28'S is effective and safe in individuals with both hepatitis C and HIV co-infection. However, it is important to coordinate treatment with both infectious disease and HIV specialists to ensure proper management of both conditions.

Weight gain or loss is not commonly reported as a side effect of the VELPACLEAR TABLET 28'S. However, individual responses to medication can vary. If you experience any unexplained or concerning changes in weight during treatment, it is recommended to consult your healthcare provider for further evaluation.

VELPACLEAR TABLET 28'S can be used in patients with a history of liver transplantation who have recurrent hepatitis C. However, individual patient factors and the specific post-transplantation period must be considered. Consultation with a transplant hepatologist or specialist is recommended to determine the most appropriate treatment approach.

While VELPACLEAR TABLET 28'S is generally well-tolerated, like any medication, it can potentially cause side effects. Common side effects include headache, fatigue, nausea, and insomnia. Serious side effects are rare but can include severe allergic reactions, changes in heart rate, and liver problems. It is important to discuss any concerns or potential side effects with your healthcare provider, who can provide further information and guidance based on your specific situation.

Before starting VELPACLEAR TABLET 28'S, you should be screened for Hepatitis B (HBV). Inform your doctor about all your current medications and medical conditions, especially kidney problems, psychiatric history, and if you are pregnant or breastfeeding.

VELPACLEAR TABLET 28'S can interact with other medications, so tell your doctor everything you are taking. Close monitoring is needed if you take amiodarone (a heart medication) or have kidney problems. Patients with current or prior Hepatitis B need close monitoring during and after treatment.

VELPACLEAR TABLET 28'S contains the active ingredients Sofosbuvir and Velpatasvir.

VELPACLEAR TABLET 28'S is used to treat chronic (long-lasting) Hepatitis C infection in adults.

VELPACLEAR TABLET 28'S is a combination of antiviral medicines that work by stopping the Hepatitis C virus from multiplying and infecting new liver cells.

Yes, VELPACLEAR TABLET 28'S is highly effective in treating various types of Hepatitis C infection, often leading to a cure.